Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Deffered Revenue (2017 - 2021)

Historic Non-Current Deffered Revenue for Summit Therapeutics (SMMT) over the last 5 years, with Q2 2021 value amounting to $365000.0.

  • Summit Therapeutics' Non-Current Deffered Revenue changed N/A to $365000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $365000.0, marking a year-over-year change of. This contributed to the annual value of $569000.0 for FY2020, which is 1541.58% up from last year.
  • Latest data reveals that Summit Therapeutics reported Non-Current Deffered Revenue of $365000.0 as of Q2 2021.
  • Summit Therapeutics' 5-year Non-Current Deffered Revenue high stood at $29.3 million for Q1 2017, and its period low was $365000.0 during Q2 2021.
  • Over the past 4 years, Summit Therapeutics' median Non-Current Deffered Revenue value was $569000.0 (recorded in 2020), while the average stood at $4.7 million.
  • Over the last 5 years, Summit Therapeutics' Non-Current Deffered Revenue had its largest YoY gain of 1832.94% in 2020, and its largest YoY loss of 1832.94% in 2020.
  • Over the past 4 years, Summit Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $29.3 million in 2017, then tumbled by 98.36% to $480861.1 in 2019, then rose by 18.33% to $569000.0 in 2020, then plummeted by 35.85% to $365000.0 in 2021.
  • Its Non-Current Deffered Revenue stands at $365000.0 for Q2 2021, versus $383000.0 for Q1 2021 and $569000.0 for Q4 2020.